A European technology group signs a term sheet with an Israeli target. The founders are cooperative, the data room goes live within days, and the financial picture looks clean. Then the legal team discovers that core software was developed under a government research grant – and the transfer of that software requires regulatory approval that nobody factored into the timeline. The deal stalls. Costs mount. The window closes. This scenario plays out with regularity in Israeli M&A transactions, precisely because Israel's commercial environment combines a sophisticated capital markets culture with regulatory layers that are unfamiliar to most foreign acquirers.
M&A due diligence in Israel follows a structured process governed by Israeli corporate legislation, intellectual property legislation, investment rules, and employment law. A foreign acquirer must review corporate records, IP ownership chains, technology transfer restrictions, and all conditions precedent before a share purchase agreement can be signed. A well-organised due diligence process typically runs four to eight weeks for a mid-market transaction.
This guide sets out the step-by-step legal due diligence process for foreign buyers in Israel, the documentary checklist, the most common errors, cost ranges, and a decision framework for different transaction types.
Why Israeli due diligence differs from other markets
Israel's legal system is rooted in English common law, inherited from the British Mandate period. It has since been supplemented by substantial domestic legislation across corporate, employment, and tax matters. For a foreign acquirer accustomed to a civil law environment, the system will feel broadly familiar – but several features make Israeli due diligence distinctly more demanding.
First, a large share of Israeli technology companies have received funding from the Rashut HaHashtala (Israel Innovation Authority, formerly the Office of the Chief Scientist). That funding carries strings. Intellectual property developed with those grants cannot be freely transferred abroad without prior approval. This rule applies not only to outright asset transfers but, in many cases, to the indirect transfer of control that occurs in a share acquisition.
Second, Israel has its own foreign investment review regime. Transactions involving defence technology, cybersecurity, or critical infrastructure require clearance under security legislation administered by the Ministry of Defence. The threshold for what qualifies as "defence-related" is broader than foreign buyers typically assume.
Third, Israeli employment law – governed by labour legislation and a dense body of collective agreements – creates obligations that do not dissolve on a share transfer. Tzav Harchava (extension orders) apply industry-wide employment terms even where no union agreement exists. Change-of-control provisions in employment contracts are common in the tech sector and must be identified early.
For a detailed view of how Israeli corporate legislation structures share acquisitions and board approvals, see our guide to corporate law in Israel.
Step-by-step due diligence process and timeline
The process below applies to a standard share acquisition of a private Israeli company. Asset deals require additional steps around title and regulatory licensing.
Step 1 – Preliminary scoping (days 1–5). Before the data room opens, the acquirer's legal team should identify the target's sector, its government funding history, and whether any regulatory approvals will be required. This scoping exercise determines the depth of review needed and whether specialist regulatory counsel must be engaged in parallel with general M&A counsel.
Step 2 – Data room opening and request list (days 5–10). The acquirer issues a due diligence request list. A comprehensive request list for an Israeli technology target covers corporate records, cap table, IP assignments, grant agreements, employment contracts, material customer and supplier agreements, litigation history, tax filings, and data protection compliance documentation. The target's counsel typically populates the data room over five to ten business days.
Step 3 – Legal review (days 10–35). The acquirer's legal team reviews all documents in the data room against the request list. Israeli corporate legislation requires that the target's register of shareholders – maintained at the Rasham HaChevrot (Israeli Companies Registry) – accurately reflects the current cap table. Discrepancies between the registry and internal shareholder records are a red flag that must be resolved before signing.
Step 4 – Follow-up queries and management interviews (days 25–40). Written queries are issued to the target's counsel. For complex IP or regulatory issues, direct management interviews may be necessary. This step frequently reveals undisclosed grant obligations or informal arrangements with founders that do not appear in the data room.
Step 5 – Due diligence report and risk matrix (days 35–50). The acquirer's counsel produces a written due diligence report. The report identifies material risks, proposed closing conditions, and issues to be addressed through representations and warranties in the heskem rechisha (share purchase agreement, commonly referred to as the SPA). A risk matrix ranks each issue by severity and allocates responsibility for resolution.
Step 6 – SPA negotiation and closing conditions (days 40–70). The due diligence findings directly shape SPA negotiations. Representations and warranties given by the sellers address each identified risk area. Closing conditions are drafted to require resolution of material issues – such as regulatory approvals or IP assignment confirmations – before the transaction completes.
To receive expert guidance on structuring the acquisition process and SPA terms, contact us at info@ferrazwhitmore.com.
The legal due diligence checklist
The following checklist covers the core documentary categories for an Israeli share acquisition. Each category maps to a specific legal risk that affects either valuation, deal structure, or post-closing integration.
Corporate standing and ownership. Obtain a current extract from the Rasham HaChevrot confirming the target's registered status, directors, and share capital. Verify the cap table against the registry. Review all shareholders' agreements, option plans, and convertible instruments. Many Israeli tech companies operate with significant option pools; dilution on closing must be calculated precisely.
Intellectual property. IP is the primary value driver in most Israeli technology acquisitions. The review must confirm that all IP created by founders, employees, and contractors has been validly assigned to the target. Under Israeli employment legislation, employees who develop IP in the course of their employment are presumed to assign that IP to their employer. but only if the employment agreement is correctly drafted and the IP falls within the scope of employment. Gaps in assignment documentation create title risk that cannot be cured post-closing without founder cooperation.
Government grants and innovation authority obligations. Request all grant agreements with the Israel Innovation Authority and any predecessor bodies. Each agreement will specify restrictions on the transfer, licensing, or manufacture abroad of the funded technology. An acquirer planning to relocate development activity outside Israel must factor in the cost of royalty repayment or approval fees before modelling deal economics.
Regulatory and defence-related approvals. Confirm whether the target holds any licences issued under security legislation or export control rules. If the target's products appear on Israeli or international export control lists, the acquisition may require Ministry of Defence clearance. This review cannot be deferred – clearance timelines can extend to several months and must be built into the transaction schedule as a closing condition.
Employment and benefits. Review all employment agreements, consulting agreements, and option grant letters. Identify any change-of-control provisions that accelerate vesting or trigger compensation obligations on closing. Confirm compliance with mandatory benefit requirements under Israeli labour legislation, including pension contributions and keren hishtalmut (continuing education fund) arrangements.
Material contracts. Review all customer agreements, supplier agreements, and distribution arrangements for assignment restrictions, change-of-control termination rights, and exclusivity obligations. SaaS contracts in the Israeli market frequently contain data localisation requirements that affect post-closing product architecture.
Litigation and regulatory proceedings. Request disclosure of all current and threatened litigation, regulatory investigations, and tax disputes. Israeli tax legislation is actively enforced; unresolved transfer pricing issues or undisclosed related-party transactions create post-closing indemnification exposure.
Data protection compliance. Israel's data protection legislation – among the most developed in the region – requires that personal data processing be properly authorised and, for cross-border transfers, that appropriate safeguards are in place. A target that processes personal data of EU residents must also comply with EU data protection rules. Non-compliance creates both regulatory and contractual risk.
Foreign buyers evaluating Israeli targets alongside acquisitions in the Gulf should review our comparative analysis in the guide to M&A due diligence in the UAE.
Common errors by foreign acquirers – and their consequences
Several patterns of error recur in Israeli M&A transactions involving international buyers. Each carries a specific cost.
The most damaging error is treating IP assignment as a formality. Foreign buyers accustomed to US or European deal conventions sometimes accept a seller's representation that "all IP is owned by the company" without obtaining the underlying assignment documentation. In Israel, where a significant proportion of technology was developed by founders operating as independent contractors before incorporation, the gap between representation and reality can be substantial. Undocumented IP creates title risk that materialises in post-closing disputes.
A second common error is failing to engage with Israel Innovation Authority grant obligations at the term sheet stage. Buyers learn about grant restrictions during due diligence but assume they can be addressed in the SPA through a warranty. This approach is inadequate. Approval from the Innovation Authority is a regulatory requirement, not a contractual one. It takes time, may impose conditions, and can affect deal economics in ways that are difficult to remedy through indemnification alone.
A third error involves change-of-control provisions in employment agreements. Israeli technology companies frequently grant key engineers and product leads contractual rights that are triggered by an acquisition. Buyers who do not review these provisions before signing the SPA may face a situation where closing the deal triggers immediate retention costs that were not priced into the transaction.
Finally, foreign buyers sometimes underestimate the importance of Israeli tax due diligence. Israeli tax legislation provides specific regimes for technology companies – including preferential rates for income derived from qualifying IP. These regimes carry conditions. A target that has benefited from preferential treatment but has not maintained compliance will carry a latent tax liability that becomes the acquirer's problem after closing.
Self-assessment checklist before proceeding
This approach is appropriate if the following conditions are met. Use this checklist before committing resources to a full due diligence process.
- The target is a private Israeli company with its primary operations and IP in Israel.
- You have confirmed, at least in preliminary form, the target's government grant history and whether any technology is subject to Israel Innovation Authority restrictions.
- You have verified that no Ministry of Defence or export control approvals are required – or, if they are, you have built the approval timeline into your transaction schedule.
- You have engaged Israeli legal counsel with experience in technology M&A, not general commercial counsel unfamiliar with the grant and defence clearance regime.
- You have identified all option holders and confirmed the post-closing cap table on a fully diluted basis.
If any of these conditions cannot be confirmed, address them before the due diligence phase begins. Discovering a disqualifying issue mid-process wastes resources on both sides and damages deal momentum.
For a tailored strategy on structuring your acquisition in Israel, reach out to us at info@ferrazwhitmore.com.
Frequently asked questions
Q: How long does M&A due diligence typically take in Israel?
A: For a mid-market technology or life sciences transaction, legal due diligence in Israel typically runs four to eight weeks. The timeline depends on the complexity of the target's IP portfolio, the number of subsidiaries, and the responsiveness of management in populating the data room. Transactions involving regulated sectors – such as defence technology or financial services – may require additional time for regulatory clearance review.
Q: Is a share purchase agreement governed by Israeli law enforceable against a foreign acquirer?
A: Yes. A share purchase agreement governed by Israeli law binds all parties regardless of their nationality or place of incorporation. Israeli courts apply commercial legislation and contract law to enforce SPA obligations, including representations and warranties, indemnification obligations, and closing conditions. Foreign acquirers should ensure that jurisdiction and governing law clauses are negotiated carefully before signing.
Q: What is the most common due diligence mistake made by foreign buyers in Israel?
A: The most frequent error is underestimating Israel's technology transfer controls. Foreign acquirers often treat Israeli targets as straightforward commercial acquisitions without recognising that defence or dual-use technology developed with government funding may be subject to mandatory approval before the acquisition can close. Engaging a lawyer in Israel with regulatory experience at the outset prevents this from becoming a deal-breaker.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border legal solutions in M&A transactions. This includes due diligence. SPA negotiation. Additionally, regulatory clearance for acquisitions in Israel and across the Asia-Pacific and Middle Eastern markets. We work with international technology investors, institutional acquirers, and in-house legal teams who require results-oriented counsel across multiple legal systems. Our M&A practice covers transactions across both civil law and common law jurisdictions. Additionally. Our attorneys have advised on share acquisition matters before Israeli regulatory bodies and in cross-border settings involving EU, US, and Israeli counterparties. As a law firm in Israel-focused transactions, we bring direct knowledge of the Israel Innovation Authority approval process, defence technology controls, and employment law obligations that affect deal structuring and closing conditions. To discuss your acquisition strategy or begin a preliminary review of your due diligence position, contact us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.